Know Cancer

or
forgot password

A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Non-small Cell Lung Cancer, Efficacy

Thank you

Trial Information

A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study


Inclusion Criteria:



1. Chemotherapy-naive patients with histologically or cytologically confirmed
adenocarcinoma and large-cell carcinoma, classified as stage IIIB not amenable to
curative treatment or stage IV

2. With at least one unidimensionally measurable lesion according to the Response
Evaluation Criteria in Solid Tumors;

3. with an Eastern CooperativeOncology Group performance status of 0 or 1,

4. At least 18 years of age

5. adequate bone marrow reserve and organ function including calculated creatinine
clearance 45 mL/min based on the standard Cockcroft and Gault formula.

6. Prior radiation therapy was permitted if it was completed at least 4 weeks before
study treatment

7. patients had fully recovered from its acute effects.

Exclusion Criteria:

1. peripheral neuropathy > National Cancer Institute Common Toxicity Criteria grade 1

2. progressive brain metastases,

3. uncontrolled third-space fluid retention before study entry.

4. Patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs
or if they were unable or unwilling to take folic acid, vitamin B12, or
corticosteroids.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival (PFS)

Outcome Time Frame:

36months

Safety Issue:

No

Principal Investigator

Li Zhang, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Cancer Center of Sun Yat-Sen University (CCSU)

Authority:

China: Food and Drug Administration

Study ID:

HANSOH20090601

NCT ID:

NCT01194453

Start Date:

November 2009

Completion Date:

June 2012

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Efficacy
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location